As RLT with 177Lu-labeled PSMA antagonists is the first RLT with PSMA to be approved for patients with advanced prostate cancer (PC), careful planning is needed to ensure the integration of RLT into care systems and to guarantee patient access [8, 12]. The gene discussed is FOLH1; the disease is pachyonychia congenita.